Attached files

file filename
10-K - FORM 10-K - SYNAGEVA BIOPHARMA CORPd10k.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - SYNAGEVA BIOPHARMA CORPdex311.htm
EX-23.1 - CONSENT OF ERNST AND YOUNG LLP - SYNAGEVA BIOPHARMA CORPdex231.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - SYNAGEVA BIOPHARMA CORPdex322.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - SYNAGEVA BIOPHARMA CORPdex321.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - SYNAGEVA BIOPHARMA CORPdex312.htm

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

Trimeris, Inc.:

 

We consent to the incorporation by reference in the registration statements (No. 333-44145, No. 333-64064, No. 333-66401, No. 333-74304, No. 333-90377, No. 333-107508, No. 333-129600, No. 333-138807, No. 333-147430, and No. 333-147431) on Forms S-8 of Trimeris, Inc. of our report dated March 12, 2009, except with respect to the adoption of FASB ASC Topic 808, Collaborative Arrangements, (as discussed in note 1 and paragraph 8 of note 7 to the December 31, 2010 financial statements) as to which the date is as of March 16, 2010, with respect to the statements of operations, stockholders’ equity, and cash flows of Trimeris, Inc. for the year ended December 31, 2008, which appears in the December 31, 2010 annual report on Form 10-K of Trimeris, Inc.

 

As discussed in note 1 and in paragraph 8 of note 7 to the December 31, 2010 financial statements, the Company adopted the provisions of FASB ASC Topic 808, Collaborative Arrangements, as of January 1, 2009 and, accordingly, adjusted the previously issued statement of operations for the year ended December 31, 2008.

 

/s/ KPMG LLP

 

Raleigh, North Carolina

March 14, 2011